ATE449342T1 - Nachweis von krebs - Google Patents

Nachweis von krebs

Info

Publication number
ATE449342T1
ATE449342T1 AT95940906T AT95940906T ATE449342T1 AT E449342 T1 ATE449342 T1 AT E449342T1 AT 95940906 T AT95940906 T AT 95940906T AT 95940906 T AT95940906 T AT 95940906T AT E449342 T1 ATE449342 T1 AT E449342T1
Authority
AT
Austria
Prior art keywords
patient
afp
cancer cells
cancer
introducing
Prior art date
Application number
AT95940906T
Other languages
English (en)
Inventor
Ricardo J Moro
Original Assignee
Ricardo J Moro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricardo J Moro filed Critical Ricardo J Moro
Application granted granted Critical
Publication of ATE449342T1 publication Critical patent/ATE449342T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5757Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95940906T 1994-09-19 1995-09-18 Nachweis von krebs ATE449342T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30814194A 1994-09-19 1994-09-19
PCT/IB1995/000902 WO1996009551A1 (en) 1994-09-19 1995-09-18 Detection and treatment of cancer

Publications (1)

Publication Number Publication Date
ATE449342T1 true ATE449342T1 (de) 2009-12-15

Family

ID=23192727

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940906T ATE449342T1 (de) 1994-09-19 1995-09-18 Nachweis von krebs

Country Status (15)

Country Link
US (1) US6514685B1 (de)
EP (3) EP1955714A1 (de)
KR (1) KR970706498A (de)
CN (2) CN100472213C (de)
AT (1) ATE449342T1 (de)
AU (1) AU714966B2 (de)
BR (1) BR9508959A (de)
CA (1) CA2197490A1 (de)
DE (1) DE69536019D1 (de)
DK (1) DK0782709T3 (de)
ES (1) ES2336976T3 (de)
FI (1) FI121353B (de)
NO (1) NO323754B1 (de)
RU (1) RU2161042C2 (de)
WO (1) WO1996009551A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
AU2003216048A1 (en) * 2002-01-10 2003-07-30 David Kleinfeld Iterative optical based histology
CA2514058C (en) * 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
CN100360684C (zh) * 2005-02-01 2008-01-09 合肥中科大生物技术有限公司 甲胎蛋白(AFP)mRNA荧光定量RT-PCR检测试剂盒
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
RU2377962C1 (ru) * 2008-06-10 2010-01-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко РАСХН(ВИЭВ) Способ диагностики лейкоза крупного рогатого скота
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) * 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
CA2778533A1 (en) * 2009-10-22 2011-04-28 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
HUE040012T2 (hu) * 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
WO2012021144A1 (en) 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (de) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazol- und thioethervernetzte peptidomimetische makrozyklen
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
MX357292B (es) 2012-07-19 2018-07-04 Toray Industries Método para detectar cáncer.
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (de) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
EP3371211B1 (de) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-assoziierte proteinkinasehemmer zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
CN106290876B (zh) * 2016-08-11 2018-06-29 湖南新大陆生物技术有限公司 一种肿瘤细胞检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2682697B2 (ja) 1989-03-29 1997-11-26 積水化学工業株式会社 免疫測定試薬および免疫測定法
FR2701710B1 (fr) * 1993-02-18 1995-04-21 Intromed Ltd Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic.

Also Published As

Publication number Publication date
DE69536019D1 (de) 2009-12-31
EP0782709A1 (de) 1997-07-09
NO971256L (no) 1997-03-18
EP1956374A1 (de) 2008-08-13
CN1132012C (zh) 2003-12-24
NO323754B1 (no) 2007-07-02
FI970990A7 (fi) 1997-03-10
AU714966B2 (en) 2000-01-13
US6514685B1 (en) 2003-02-04
KR970706498A (ko) 1997-11-03
WO1996009551A1 (en) 1996-03-28
FI970990A0 (fi) 1997-03-10
EP1955714A1 (de) 2008-08-13
FI121353B (fi) 2010-10-15
RU2161042C2 (ru) 2000-12-27
DK0782709T3 (da) 2010-03-29
BR9508959A (pt) 1997-12-30
CN1502994A (zh) 2004-06-09
AU3764895A (en) 1996-04-09
EP0782709B1 (de) 2009-11-18
NO971256D0 (no) 1997-03-18
CN1169778A (zh) 1998-01-07
ES2336976T3 (es) 2010-04-19
CA2197490A1 (en) 1996-03-28
CN100472213C (zh) 2009-03-25

Similar Documents

Publication Publication Date Title
ATE449342T1 (de) Nachweis von krebs
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE246356T1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
NO904001D0 (no) Fremgangsmaate og anordning for amperometrisk diagnoseanalyse.
ATE126354T1 (de) Vorrichtung und verfahren zur bestimmung eines analyten in einer flüssigen probe mittels folgereaktionen.
ATE159982T1 (de) Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
ATE297950T1 (de) Testverfahren und reagenzien zur quantifizierung von hbnp
DE68924779D1 (de) Vorrichtung und verfahren zum nachweis von chemischen spezies.
NO940901L (no) Gensöker-biosensor-metode
ATE137583T1 (de) Verfahren und vorrichtung zur bestimmung von chemischen spezies in körperflüssigkeit
DE3584796D1 (de) Verfahren und vorrichtung zur durchfuehrung analytischer bestimmungen.
RU97106059A (ru) Обнаружение и лечение рака
DE68925058D1 (de) Verfahren zum frühzeitigen Nachweis von Lungenkrebs
FR2760838B1 (fr) Circuit fluidique integre d'execution d'un processus de preparation ou d'analyse d'un echantillon de matiere fluide, son procede de fabrication et appareil d'exploitation de ce circuit
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE157172T1 (de) Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie
DE59606129D1 (de) Verfahren und verbindungen zur detektion von analyten mittels remanenzmessung und deren verwendung
DE69513649D1 (de) Verfahren zum nachweis der gegenwart einer mykobakterien-spezies und testsatz sowie antikörpes zur verwendung in diesem verfahren
DE3485265D1 (de) Verfahren zur bestimmung eines polyvalenten antigens und reagenz hierfuer.
ES2122292T3 (es) Diagnosis precoz de sepsis utilizando interacciones antigeno-anticuerpo amplificadas por quimioluminiscencia de sangre completa.
DE69521145D1 (de) Verfahren zur kompetitiven bestimmung eines haptens
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
RU97100364A (ru) Способ для обнаружения и оценки концентрации анаэробных бактерий в биологическом субстрате
DE69922680D1 (de) Detektion und quantifikation von vancomycin in den biologischen flüssigkeiten
ATE483734T1 (de) Vorrichtung und verfahren zur bestimmung des eintretens und vorhandenseins septischer bedingungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties